BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

If, as ivonescimab’s victory over Keytruda suggested, PD-(L ... Akeso and Summit are leading the race, but BioNTech is well ...

Jemperli plus chemotherapy demonstrated superior overall survival compared to Keytruda in advanced NSCLC, with a median OS of ...

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based ...

Vernon Bernardino has given his Buy rating due to a combination of factors, including promising preliminary results from Citius Pharmaceuticals’ ongoing clinical trial of Lymphir in combination with ...

Aethlon Medical has enrolled the first patient in its Australian clinical trial evaluating the safety, feasibility, and ...

Aethlon Medical (AEMD) announced enrollment of the first patient in its Australian safety, feasibility and dose-finding clinical trial of the ...

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...